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To evaluate the safety and eﬃcacy of Tien-Hsien Liquid Practical (THL-P), a Chinese herbal mixture, in patients with refractory
metastatic breast cancer, we performed a randomized, double-blind, placebo-controlled, parallel-group, phase IIa pilot trial.
Patients were randomly assigned to either receive THL-P or matching placebo and followed up every 4 weeks for 24 weeks.
The primary endpoint was changes in the global health status/quality of life (GHS/QOL) scale. The secondary endpoints were
changes in functional and symptom scales, immunomodulating eﬀects, and adverse events. Sixty-three patients were enrolled
between June 2009 and June 2011. The intent-to-treat population included 28 patients in the THL-P group and 11 patients in
the placebo group. Compared to the placebo group, the THL-P group had signiﬁcant improvement from baseline to last visit in
GHS/QOL (41.7 versus −33.3; P<0.05), CD3, CD4/CD8, CD19, CD16+56 positive cells (P<0.05), and higher levels of physical,
role, emotional, and cognitive functioning, as well as decreased fatigue and systemic side eﬀects. Treatment-related adverse events
were mild constipation and localized itching, and no serious adverse events were reported. THL-P appears to be a safe alternative
adjuvant treatment for patients with refractory metastatic breast cancer, as it eﬀectively improves QOL and palliates cancer-related
symptoms.
1.Introduction
Breast cancer, a leading cause of morbidity and mortality
among women, was estimated to account for 23% (1.38mil-
lion)ofnewcancercasesand14% (458,400) ofcancerdeaths
worldwide in 2008 [1, 2]. In Taiwan, breast cancer was the
most common cancer among women, with an incidence of
9,049 cases per 100,000 population, and the fourth leading
cause of cancer-related deaths in 2008 [3]. Despite advances
in the treatment of breast cancer, it is estimated that 30–50%
ofwomeninitiallydiagnosedwithearlierstagesofbreastcan-
cer eventually develop metastatic disease [4]. Unfortunately,
breast cancer has a poor prognosis following metastasis, and
women with metastatic breast cancer have a limited survival
of 18–24 months and a 5-year survival rate of approximately
20% [2, 5]. The progression to metastatic disease is further
exacerbated by the increasing use of chemotherapy in early-
stagebreastcancer,whichhasledtoacorrespondingincrease
in the number of metastatic breast cancer cases refractory to
conventional treatments [4].
The currently available conventional treatment options
for metastatic breast cancer include cytotoxic chemotherapy,
endocrine/hormonal therapy, targeted biological therapy, ra-
diation therapy, bisphosphonates, or combinations of these,
andsurgeryinsomecases[2,4,5].However,thereisnoglob-
al consensus and guidelines for the treatment of metastatic2 Evidence-Based Complementary and Alternative Medicine
breast cancer, and treatment is highly individualized and
varies worldwide. Furthermore, due to the poor prognosis of
metastatic breast cancer, the main goals of treatment are pal-
liative rather than curative. Speciﬁcally, treatment is aimed
at prolonging progression-free survival (PFS) and overall
survival (OS), managing or reducing disease symptoms, and
achieving the best quality of life (QOL) [4, 5]. However, the
signiﬁcantsideeﬀects,potentialforthedevelopmentoftreat-
ment resistance, and limited survival beneﬁt associated with
conventional treatments have prompted the use of comple-
mentary and alternative medicine (CAM) in patients with
advanced malignancies [4, 6–8].
The use of CAM has been on the rise, especially among
patients with life-threatening diseases, such as cancer [9]. In
fact, it has been estimated that 48–98% of breast cancer pa-
tientsuseCAM,andthemostcommonlyusedCAMisherbal
medicine [10–13]. There are numerous reasons cited by
breast cancer patients for using CAM, including strengthen-
ingtheimmunesystem,increasingQOL,treatingorprevent-
ing the recurrence of cancer, stabilizing current condition,
alleviating cancer-related symptoms, assisting conventional
treatments, relieving symptoms and stress associated with
side eﬀects of conventional treatments, providing a feeling of
controloverlife,reducingstressanddetoxiﬁcation,andcom-
pensating for failed conventional medical treatments [10, 12,
13]. Although CAM is widely used by breast cancer patients,
their safety and eﬃcacy have been studied in very few rando-
mized and controlled clinical trials [13].
Tien-Hsien Liquid Practical (THL-P), a Chinese herbal
mixture, has been used as a CAM foroverten years.Recently,
THL-P has been shown to have strong immunomodulating
and anticancer eﬀects via a number of preclinical in vitro
and in vivo experiments [6, 7, 9, 14, 15]. Speciﬁcally, THL-P
has been shown to modulate the antigen-stimulated prolif-
eration response and cytokine production of T-lymphocytes,
inhibit cell growth and induce apoptosis in various human
cancer cell lines and possess antitumour, antiangiogenic,
antimetastatic eﬀects [6, 7, 9, 14, 15]. Based on these prom-
ising ﬁndings, we performed a randomized, double-blind,
placebo-controlled, parallel-group, phase IIa pilot trial to
evaluate the safety and eﬃcacy proﬁles of THL-P in patients
with metastatic breast cancer refractory to conventional
treatments.
2. Methods
2.1. Study Design. This study was a randomized, double-
blind,placebo-controlled,parallel-group,phaseIIapilottrial
in patients with metastatic breast cancer refractory to con-
ventional treatment modalities. The primary outcome was
thechangesfrombaselinetoposttreatmentevaluationsinthe
global health status/quality of life (GHS/QOL) standardized
scale, assessed by the self-administered European Organiza-
tion for Research and Treatment of Cancer Quality of Life
Questionnaire-Core 30 (EORTC-QLQ-C30). The secondary
outcomes included changes in functional and symptom
scales, as well as the single items, of the EORTC-QLC-Q30
and -Breast Cancer 23 (BR23), immunomodulating eﬀects
of treatment on lymphocytes, and treatment-related adverse
events. The study was approved by the Institutional Review
Board (IRB) of the National Taiwan University Hospital, and
written informed consents were obtained from all patients
prior to entering the trial.
2.2. Participants. Subjects were recruited at the National
Taiwan University Hospital in Taipei, Taiwan between June
2009andJune2011.Theinclusioncriteriawerewomen,aged
20 to 80 years old, who had histologically or cytologically
conﬁrmed breast cancer with clinical evidence of progressive
metastatic disease and any one of the following: (a) no sat-
isfactory response after primary or salvage treatment (i.e.,
chemotherapy, radiotherapy, surgery, or other approved
therapies, such as target therapy or immunotherapy) and (b)
no intention of accepting additional conventional treat-
ments. Subjects were included provided that they had ad-
equate bone marrow function with an absolute neutrophil
count ≥1000/μL, hemoglobin count ≥8g/dL, and platelet
count >75,000/μL, and liver and renal function with total
serum bilirubin <3mg/dL and serum creatinine <2mg/dL,
respectively. Subjects of childbearing potential had to agree
to use medically accepted means of contraception during the
participation of the study. Subjects must also have an esti-
mated life expectancy of at least 4 weeks. All subjects had to
give written informed consent to participate in the study.
Subjects were excluded if they have ever received radio-
therapy, endocrine therapy, antineoplastic drugs, or hor-
monal agents as adjuvant treatment or therapy for metastatic
breast cancer within 2 weeks prior to entering the study.
Additional exclusion criteria included uncontrolled infec-
tions, history of autoimmune disease (i.e., lupus erythema-
tosus, ankylosing spondylosis, scleroderma or multiple scle-
rosis),priorhistoryofothermalignancies,withtheexception
of skin basal cell carcinoma, within 3 years of study entry, or
any other serious diseases or medical history considered by
theinvestigatortoplacethesubjectatincreasedrisk.Subjects
with aspartate aminotransferase (AST) and alanine amino-
transferase (ALT) levels above ﬁve times the upper limit of
normal values, or if liver metastases were present, above ten
times the upper limit of normal values, were excluded.
Womenwhowerelactating,pregnant,orplanningtobecome
pregnantwerealsoexcluded.Lastly,subjectswerenoteligible
if they had participated in any other investigational study
within 4 weeks of study entry.
Subjects were withdrawn from the study if any of the
following criteria were met: (a) subject decided to withdraw
her informed consent, (b) the investigator considered the
subject to be no longer physically or psychologically capable
of remaining in the study, (c) subject refused to proceed
with critical measures for the study endpoints, deﬁned as all
variables required for the primary endpoint analysis, or (d)
subjectdevelopedadverseeﬀectsthattheinvestigatorconsid-
ered as warranting discontinuation of the study treatment.
2.3. Treatment Groups. T h es t u d yg r o u pr e c e i v e d1v i a l
(20mL) of THL-P oral solution 3 times per day for 24 weeks.
THL-P is an aqueous preparation that consists of extracts
from 14 Chinese medicinal herbs, 11 of which are activeEvidence-Based Complementary and Alternative Medicine 3
ingredients and the remaining three are ﬂavoring ingredi-
ents. The active ingredients of THL-P oral solution (Sheng
Foong Co., Ltd., I-Lan County, Taiwan) are Atractylodes ma-
crocephala (250mg/mL), Astragalus membranaceus (330mg/
mL), Taraxacum mongolicum (500mg/mL), Poria cocos
(330mg/mL), Ligusticum chuanxiong (250mg/mL), Ligus-
trum lucidum (250mg/mL), Codonopsis pilosula (250mg/
mL), Glycyrrhiza uralensis (160mg/mL),H e d y o t i sd i ﬀusa
(330mg/mL), Pseudostellaria heterophylla (250mg/mL), and
Viola philippica (160mg/mL). The compositions, as well as
the pharmacological and immunological eﬀects, of these
ingredients, have been previously described [14, 15]. The
control group received 1 vial (20mL) of a matched placebo
3 times per day for 24 weeks. The matched placebo consisted
of food-grade ﬂavoring ingredients, which ensured a similar
appearance, taste, and odor to the THL-P oral solution, and
was dispensed in a similar opaque plastic bottle.
The investigators attempted to minimize the use of con-
comitant treatments in each subject throughout the study.
If concomitant treatments were deemed necessary by the
investigator, then it was ensured that a stable dose and ther-
apy type were maintained throughout the study to minimize
potential interference with the study endpoint assessments.
Antipyretics on the day of injection were permitted, whereas
all cancer treatments, with the exception of non-study-
relatedlocallesionspalliativeradiationtherapy,wereprohib-
ited during the study.
2.4. Randomization and Blinding. Treatment allocation was
performed prior to site initiation, and each patient was
assigned a unique number based on the order of enrolment.
Patients meeting the eligibility criteria were randomly as-
signed in a 2:1 ratio to either the THL-P treatment or
placebo group. Randomization was achieved with the use of
apermuted-blockrandomization algorithmwithablocksize
of 6 in SAS 9.0 software (SAS Institute Inc., Cary, NC, USA),
where a list of sequential numbers was generated with each
number randomly assigned to a group. All patients, care-
givers, investigators, and outcome assessors were blinded to
treatment assignment.
2.5. Measurement of Outcomes. After randomization, several
examinations were conducted at baseline and followed up
every 4 weeks for 24 weeks. The examinations included self-
administered EORTC-QLQ-C30, EORTC-QLC-Q30 and
-Breast Cancer 23 (BR23), body weight, collection of blood
for assessment of T-lymphocyte activity, biochemistry, and
hematology tests.
The primary endpoint was to evaluate the eﬃcacy of the
treatment in improving the QOL of patients from baseline to
last visit. The changes in the GHS/QOL scale were assessed
by the self-administered EORTC-QLQ-C30. The secondary
outcomes evaluated the eﬃcacy and safety of the treatment.
The eﬃcacy of the treatment was evaluated between baseline
and last visit via the following measures: (a) changes and
maximum improvements in the functional and symptom
standardizedscales,aswellasthesingleitems,oftheEORTC-
QLC-Q30and-BreastCancer23(BR23),(b)changesinbody
weight, (c) immunomodulating eﬀects of treatment on lym-
phocytes, as determined via phenotypic analyses of lympho-
cytesbyﬂowcytometry(FACSCalibur,BD)withmonoclonal
antibodies for CD3, CD4, CD8, CD19, and CD16+56, and
BDMultiSETsoftware.Thesafetyofthetreatmentwasdeter-
mined from the reports of adverse events.
2.6. Statistical Analyses. T h es a m p l es i z ef o rt h i ss t u d yw a s
arbitrarily determined to be 60 subjects for this pilot study
to collect useful information for further study in the future.
Demographic and clinical characteristics at baseline were
analyzed according to randomized treatment groups. Pri-
mary and secondary endpoints were analyzed based on the
intent-to-treat (ITT) population, which was deﬁned as all
randomized patients that received any treatment. Data of
continuous variables are presented as mean ± standard de-
viation. When the normality of these variables cannot be
assumed, the data are presented as median (interquartile
range). Data of categorical variables are presented as num-
bers (percentages). Statistical comparisons between continu-
ous variables were made using the independent, two-sample
t-test. The Mann-Whitney U test was used to compare inde-
pendent groups of data that were not normally distributed.
A Fisher’s exact test was used for comparisons of categorical
variables. A parametric Student’s paired t-test or nonpara-
metric Wilcoxon signed ranks test were used to compare
diﬀerences before and after treatment in each group. For all
analyses, a two-sided P value of <0.05 was considered signi-
ﬁcant. Our primary hypothesis is that there would be a signi-
ﬁcant improvement in the QOL between baseline and last-
visit assessments in the THL-P versus placebo groups.
Statistical analyses were performed using SPSS 15.0 statistics
software (SPSS Inc, Chicago, IL, USA) and SAS 9.0 (SAS
Institute Inc., Cary, NC, USA).
3. Results
3.1. Study Population. A total of 63 patients entered our trial
between June 2009 and June 2011, and 19 patients were
excluded due to lack of conﬁdence in the treatment (n = 10),
hospital transfer (n = 2), and treatment refusal (n = 7).
Overall, the screening failure rate was 30.2%, and 44 patients
were randomly assigned in a 2:1 ratio to either the THL-P
group (n = 30) or the placebo group (n = 14) (Figure 1).
Of these 44 patients, 39 had metastasis in bone, 19 in liver,
18 in lung, and 4 in brain. The demographic and clinical
characteristics of the 44 randomized patients are summa-
rized in Table 1. There were no statistically signiﬁcant dif-
ferences between the THL-P and placebo groups in age,
height, body weight, stage of cancer (i.e., according to the
TNM classiﬁcation), duration of onset, and the scales and
single items of the EORTO-QLQ-C30. Of the patients that
were randomized to treatment, 31 patients (70.5%) did not
complete the study. Their withdrawal reasons were listed in
Figure 1. In the THL-P group, 13 patients completed the
study, while none of the patients in the placebo group com-
pleted the study. Interestingly, all of the participants in the
placebo group withdrew prior to week 12, whereas only 114 Evidence-Based Complementary and Alternative Medicine
THL-P
(n = 30)
Placebo
(n = 14)
Randomized
(n = 44)
Patients screened
(n = 63)
Excluded (n = 19)
Lack of conﬁdence in treatment (n = 10)
Hospital transfer (n = 2)
Treatment refusal (n = 7)
Analysis
(n = 28)
Excluded from ITT
(n = 2)
Analysis
(n = 11)
Excluded from ITT
(n = 3)
Completed study
(n = 13)
Withdrawn
(n = 15)
Completed study
(n = 0)
Withdrawn
(n = 11)
Figure 1: Flow diagram of the randomized, double-blind, placebo-controlled, parallel-group phase IIa clinical trial comparing Tien Hsien
liquidpractical (THL-P)toplacebo for safetyandeﬃcacy. Atotalof 63patients enteredour trialbetween June2009andJune2011.Nineteen
patients were excluded due to lack of conﬁdence in the treatment (n = 10), hospital transfer (n = 2), and treatment refusal (n = 7). Forty-
four patients were randomly assigned in a 2:1 ratio to either the THL-P group (n = 30) or the placebo group (n = 14). Thirteen patients in
the THL-P group and none in the placebo group had completed the study.
participants (39.3%) in the THL-P group withdrew prior to
week 12. The ITT population was comprised of 39 patients,
with 28 patients in the THL-P group and 11 patients in the
placebo group (Figure 1).
3.2. Eﬃcacy. The primary endpoint, in particular, changes
in the GHS/QOL standardized scale between the baseline
and last visit of the ITT population, is presented in Figure 2.
There was a signiﬁcant diﬀerence between the THL-P and
placebo group with respect to the change in the GHS/QOL
scale from the baseline and last visit (41.69 versus −33.33;
P<0.001, Table 2, Figure 2). These ﬁndings indicate that
patients administered THL-P had a higher and improved
QOL than those receiving a matched placebo. Thus, THL-P
appears to be eﬃcacious in improving the QOL of patients
with refractory metastatic cancer.
Table 2 presentstheprimaryendpointsforchangesinthe
standardized functional and symptom scales, as well as the
single items, of the EORTO-QLQ-C30. There were signiﬁ-
cant diﬀerences in the changes from baseline to last visit in
four out of ﬁve functional scales (i.e., physical, role, emo-
tional,andcognitivefunctions),aswellasonesymptomscale
(i.e., fatigue), between the THL-P and placebo groups (P<
0.05). Indeed, the THL-P group appears to have improve-
ments in these scales compared to the placebo group. There
were no signiﬁcant diﬀerences from baseline to last visit in
the single items (i.e., dyspnoea, insomnia, loss of appetite,
constipation, diarrhoea, and ﬁnancial diﬃculties) of the
EORTO-QLQ-C30 between the groups.
The secondary endpoints for changes in the standardized
functional and symptom scales the EORTO-QLQ-BR23 are
presented in Table 3. There was a signiﬁcant decrease in the
changes from baseline to last visit in the “systemic therapy
∗
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Figure 2: Primary endpoint of the intent-to-treat population.
Changes in the standardized score of the global health/quality of
life (GHS/QOL) scale of the European Organization for Research
and Treatment of Cancer Quality of Life Questionnaire-Core 30
(EORTO-QLQ-C30) in the intent-to-treat population. Treatment
of Cancer Quality of Life Questionnaire-Core 30 (EORTO-QLQ-
C30). Values represent medians (interquartile ranges). ∗P<0.05
versus placebo (Mann-Whitney U test).
side eﬀects” scale between the THL-P and placebo groups
(P<0.05). Lastly, there were no signiﬁcant diﬀerences in the
body weights (i.e., % change) of the two groups between the
baseline and last visit (Table 3).
3.3. Safety. The treatment-related adverse events reported
during the study were mild constipation (n = 6) and local-
ized itching (n = 1). Constipation was relieved by increasingEvidence-Based Complementary and Alternative Medicine 5
Table 1: Demographic and clinical characteristics of patients with refractory metastatic breast cancer at baseline.
THL-P (n = 30) Placebo (n = 14) P value
Demographics
Age (years)a 60.7 ±9.55 8 .7 ±7.6 0.507
Height (cm)a 155.3 ± 5.9 156.5 ±5.4 0.512
Weight (kg)a 57.6 ±8.15 9 .3 ±10.5 0.554
Ts t a g e ,n (%)b
T1 4 (13.4) 1 (7.2)
0.968 T2 12 (40.0) 7 (50.0)
T3 7 (23.3) 3 (21.4)
T4 7 (23.3) 3 (21.4)
Lymph nodes, n (%)b
N0 10 (33.3) 3 (12.4)
0.306 N1 6 (20.0) 2 (14.3)
N2 4 (13.4) 2 (14.3)
N3 10 (33.3) 7 (50.0)
Metastasis, n (%)b
M1 30 (100) 14 (100) N/A
Duration of onset (years)c 3.5 (2.0, 7.0) 4.1 (2.7, 5.4) 0.970
EORTO-QLQ-C30
GHS/QOLc 37.5 (16.7, 50.0) 50.0 (25.0, 66.7) 0.082
Functional scales
Physicalc 60.0 (46.7, 73.3) 70.0 (46.7, 86.7) 0.336
Rolec 66.7 (33.3, 83.3) 66.7 (33.3, 100.0) 0.643
Emotionalc 66.7 (50.0, 83.3) 75. 0 (58.3, 91.7) 0.469
Cognitivec 66.7 (50.0, 83.3) 83.3 (66.7, 83.3) 0.118
Socialc 66.7 (33.3, 100.0) 66.7 (66.7, 100.0) 0.711
Symptom scales
Fatiguec 55.6 (33.3, 66.7) 38.9 (22.2, 55.6) 0.273
Nausea and vomitingc 0 (0, 16.7) 0 (0, 0) 0.362
Painc 33.3 (0, 66.7) 8.3 (0, 50.0) 0.382
Single items
Dyspnoeac 33.3 (0, 66.7) 0 (0, 33.3) 0.069
Insomniac 33.3 (0, 33.3) 33.3 (0, 66.7) 0.608
Appetite lossc 33.3 (0, 66.7) 0 (0, 33.3) 0.367
Constipationc 0 (0, 33.3) 0 (0, 33.3) 0.403
Diarrhoeac 0 (0, 0) 0 (0, 33.3) 0.523
Financial diﬃcultiesc 33.3 (0, 33.3) 33.3 (0, 33.3) 0.746
THL-P:Tien-Hsienliquidpractical:EORTO-QLQ-C30:EuropeanOrganizationforResearchandTreatmentofCancerQualityofLifeQuestionnaire-Core 30;
GHS: global health status; QOL: quality of life.
P values were determined via the independent, two sample t-testa, Fisher’s exact testb, and Mann-Whitney U testc.V a l u e sa r ep r e s e n t e da sm e a n± standard
deviationa,n u m b e r( p e r c e n t a g e ) b, and median (interquartile)c.
water intake, and itching subsided immediately after cessa-
tion of all medication. No nausea, vomiting, hair loss, diar-
rhoea, and heavy constipation were observed. Nine severe
adverse events were reported by ﬁve participants. However,
all serious adverse events were considered unrelated to THL-
P treatment by the IRB.
3.4. Immunomodulating Eﬀects. There were signiﬁcant dif-
ferences in the changes from baseline to the last visit in CD3,
CD4/CD8, CD19, and CD16+56 positive cells between the
THL-P and placebo groups (P<0.05) (Table 3). Speciﬁcally,
compared with placebo, THL-P appears to have elevated the
levels of CD3, CD4/CD8, CD19, and CD16+56 positive cells.
4. Discussion
In patients with refractory metastatic breast cancer, the oral
administration of 20mL THL-P three times a day for 24
weeks signiﬁcantly improved the QOL, increased the physi-
cal, role, emotional, and cognitive functioning, decreased
fatigue and systemic therapy side eﬀects, and had immuno-
modulating eﬀects on lymphocytes. Furthermore, THL-P6 Evidence-Based Complementary and Alternative Medicine
Table 2: Primary endpoints: Changes in the functional and symptom scales of EORTO-QLQ-C30 in the intent-to-treat population.
THL-P (n = 28) Placebo (n = 11) P-value
Change from baseline
EORTO-QLQ-C30
GHS/QOL 41.7 (29.2, 50.0)† −33.3 (−33.3, 0)† <0.001∗
Functional scales
Physical 13.3 (3.3, 26.7)† 0( −13.3, 13.3) 0.014∗
Role 0 (0, 41.7)† 0( −16.7, 0) 0.018∗
Emotional 8.3 (0, 25.0)† 0( −33.3, 8.3) 0.024∗
Cognitive 16.7 (0, 16.7)† 0( −33.3, 0) <0.001∗
Social 0 (0, 33.3)† 0( −33.3, 33.3) 0.379
Symptom scales
Fatigue −22.2 (−33.3, −11.1)† 0( −11.1, 22.2) <0.005∗
Nausea and vomiting 0 (0, 0) 0 (0, 16.7) 0.656
Pain 0 (−25.0, 16.7) 0 (0, 16.7) 0.124
Single items
Dyspnoea 0 (−33.3, 0) 0 (0, 0) 0.528
Insomnia 0 (0, 16.7) 0 (0, 33.3) 0.569
Appetite loss 0 (0, 0) 0 (0, 0) 0.633
Constipation 0 (−16.7, 0) 0 (0, 0) 0.770
Diarrhoea 0 (0, 33.3) 0 (0, 33.3) 0.866
Financial diﬃculties 0 (0, 0) 0 (0, 0) 0.747
THL-P:Tien-Hsienliquidpractical;EORTO-QLQ-C30:EuropeanOrganizationforResearchandTreatmentofCancerQualityofLifeQuestionnaire-Core 30.
∗P<0.05 versus placebo (Mann-Whitney U test). †P<0.05 versus baseline (Wilcoxon signed ranks test). Values are presented as median (interquartile).
Table 3: Secondary endpoints: changes in the functional and symptom scales of EORTO-QLQ-BR23, lymphocytes, and body weight in the
intent-to-treat population.
THL-P (n = 28) Placebo (n = 11) P value
Change from baseline
EORTO-QLQ-BR23
Functional scalesa
Body image 0 (0, 33.3)† 0 (0, 8.3) 0.346
Sexual function 0 (0, 0) 0 (0, 0) 0.591
Sexual enjoyment 0 (0, 0) 16.7 (0, 33.3) 0.582
Future perspective 16.7 (0, 33.3)† 0 (0, 0) 0.102
Symptom scalesa
Systemic therapy side eﬀects −4.8 (−23.8, 0)† 4.8 (−4.8, 9.5) 0.010∗
Breast symptoms 0 (−16.7, 8.3) 0 (−8.3, 0) 0.450
Arm symptoms −5.6 (−33.3, 0)† 0( −11.1, 22.2) 0.346
Upset by hair loss −33.3 (−33.3, 0)† 0( −16.7, 0) 0.316
Lymphocytes (%)
CD3 6.0 (1.0, 9.5)† −2.5 (−6.0, −1.0) 0.001∗
CD4 0.0 (−2.0, 8.0) −1.5 (−4.0, 1) 0.157
CD8 −1.5 (−3.0, 1.5) 0.5 (−2.0, 2.0) 0.387
CD4/CD8 0.2 (−0.1, 0.5)† −0.1 (−0.2, 0.0) 0.043∗
CD19 3.0 (0.0, 7.5)† −2.0 (−3.0, 3.0) 0.021∗
CD16+56 8.0 (3.0, 11.0)† −4.0 (−6.0, −3.0)† <0.001∗
Body weight (%)b 0.2 ± 3.4 0.3 ± 4.0 0.964
THL-P: Tien Hsien liquid practical; EORTO-QLQ-BR23: European Organization for Research and Treatment of Breast Cancer-Speciﬁc Quality of Life
Questionnaire.
∗P < 0.05 versus placebo (Mann-Whitney U testa or independent, two-sample testb).
†P<0.05 versus baseline (Wilcoxon signed ranks testa or paired Student’s t-testb). Values are presented as median (interquartile)a and mean ± standard
deviationb.Evidence-Based Complementary and Alternative Medicine 7
treatment did not induce any severe adverse events, and the
only side eﬀects reported were mild constipation and local-
ized itching. Together, these ﬁndings suggest that THL-P is a
safeandeﬀectiveCAMforpatientswithrefractorymetastatic
breast cancer.
Currently, no global consensus or guidelines exist for the
treatmentofpatientswithmetastaticbreastcancer,especially
for those refractory to conventional treatments [4, 5]. Fur-
thermore, it is estimated that anywhere from 48 to 98% of
all breast cancer patients use some form of CAM [10–13].
Interestingly,achievingthebestqualityoflife(QOL)isoneof
the main goals of conventional treatments, as well as reasons
for using CAM [4, 5, 10, 12, 13]. It was recently reported that
the GHS/QOL scale, assessed via the EORTC-QLQ-C30, can
serve as an important predictor of response to treatment,
PFS, and OS in women with metastatic breast cancer [16].
In the present study, which used the same questionnaire to
assess the GHS/QOL, as well as the function and symptom
scales,foundthatTHL-PwaseﬀectiveinimprovingtheQOL
and functions of refractory metastatic breast cancer patients.
Given these positive ﬁndings, larger trials examining the
eﬀects of THL-P on other pertinent outcomes, such as PFS
and OS, are warranted.
The use of CAM has been on the rise worldwide, espe-
cially among patients with life-threatening diseases, such as
cancer [9]. There are also marked cultural diﬀerences in the
way CAM is integrated into breast cancer treatment regi-
ments [13]. In Asian populations, including Taiwan, the use
of traditional Chinese medicines is very common and enjoys
widespread popularity [13, 17]. However, the use of CAM
may be associated with severe adverse eﬀects or CAM-drug
interactions with conventional treatments for breast cancer,
and consequently their safety and eﬃcacy warrant investiga-
tion via randomized and controlled clinical trials [13, 18]. In
this randomized, double-blind, placebo-controlled, parallel-
group, phase IIa trial, it was found that THL-P was not only
aneﬀectiveCAMinpatientswithrefractorymetastaticbreast
cancer, but also a safe alternative adjuvant, since there were
no serious adverse events reported with its use. Although
these ﬁndings suggest that the use of THL-P is safe and eﬀec-
tive,studiesthatexaminethesafetyofusingTHL-P,aswellas
other CAMs, in combination with conventional treatments
are needed.
In the present study, there were more withdrawal cases in
theplacebogroupthanintheTHL-Ptreatmentgroup.Given
that this was a double-blinded study, where the patients,
caregivers, investigators, and outcome assessors were blinded
to treatment, we speculate that the signiﬁcant diﬀerence in
the number of withdrawal cases between the control and
study groups suggests that THL-P may have possible ther-
apeutic eﬀects in patients with refractory metastatic breast
cancer, which requires further investigation.
Although not directly studied, the therapeutic eﬃcacy
of THL-P in patients with metastatic breast cancer can be
extended to its antimetastatic, antiangiogenic, and antitu-
mour eﬀects, as previously demonstrated via in vitro and
in vivo preclinical studies [6]. Furthermore, corroborating
the observations of the present study, THL-P was also found
not to have any adverse eﬀects on the body weights of
immunocompromised mice [6]. In addition to its anticancer
eﬀects, THL-P was found to have immunomodulating ef-
fects, speciﬁcally in reducing cytokine production of T-
lymphocytes isolated from patients with recurrent aphthous
ulcerations[14,15].Herein,wealsodemonstratedthatTHL-
P has immunomodulating eﬀects in patients with refractory
metastatic breast cancer. Speciﬁcally, we found that there
were marked diﬀerences in the changes from baseline to the
last visit in CD3, CD4/CD8, CD19, and CD16+56 positive
cells between the THL-P and placebo groups. Although our
study provided the ﬁrst clinical evidence for the safety and
eﬃcacyofusingTHL-Pinrefractorymetastaticbreastcancer
patients, future studies assessing the speciﬁc mechanisms
responsible for its immunomodulating eﬀects in this popu-
lation are warranted.
CAMs are widely used by breast cancer patients; however
their safety and eﬃcacy have been studied in very few rando-
mized and controlled clinical trials [8, 13, 19]. The present
study is one of a few to provide safety and eﬃcacy evidence
for a CAM that was beyond empirical evidence, case studies,
and hypothetical physiological eﬀects. Despite these impor-
tant ﬁndings, there are several limitations in the present
study, including that this was a single-site study with a small
sample size and that THL-P is a compound with multiple
ingredients. Therefore, further investigations on the exact
therapeutic mechanisms for each ingredient of THL-P, as
well as multiple site-, large-scale studies that conﬁrm and
extend the safety and eﬃcacy ﬁndings of the present study,
are warranted. However, it should be mentioned that, to our
best knowledge, there are no studies reporting that the active
ingredients of THL-P have any estrogenic eﬀects or pose a
risk for increased tumour growth [20–30].
5. Conclusions
Our ﬁndings suggest that an oral administration of 20mL
THL-P three times a day for 24 weeks signiﬁcantly improves
the QOL, increases the physical, role, emotional, and cogni-
tive functioning, decreases fatigue and systemic therapy side
eﬀects, and has immunomodulating eﬀects on lymphocytes
in patients with refractory metastatic breast cancer. Addi-
tionally, THL-P treatment did not induce any severe adverse
events. Together, these ﬁndings suggest that THL-P is a safe
and eﬀective CAM for patients with refractory metastatic
breast cancer.
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